A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Lanasa, MD
One MedImmune Way,Gaithersburg,Maryland,United States
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
44 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Greater Sudbury, Ontario, Canada
- Research Site
Hamilton, Ontario, Canada
- Research Site
Newmarket, Ontario, Canada
- Research Site
Toronto, Ontario, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Moscow, Russia
- Research Site
Moscow, Russia
- Research Site
Novosibirsk, Russia
- Research Site
Omsk, Russia
- Research Site
Saint Petersburg, Russia
- Research Site
Saint Petersburg, Russia
- Research Site
Saint Petersburg, Russia
- Research Site
Incheon, South Korea
- Research Site
Seoul, South Korea
- Research Site
Seoul, South Korea
- Research Site
Seoul, South Korea
- Research Site
Seoul, South Korea
- Research Site
Barcelona, Spain
- Research Site
Madrid, Spain
- Research Site
Madrid, Spain
- Research Site
Málaga, Spain
- Research Site
Santiago de Compostela, Spain
- Research Site
Kaohsiung City, Taiwan
- Research Site
Kaohsiung City, Taiwan
- Research Site
Taichung, Taiwan
- Research Site
Tainan, Taiwan
- Research Site
Taipei, Taiwan
- Research Site
Taipei, Taiwan
- Research Site
Taipei, Taiwan
- Research Site
Taoyuan City, Taiwan
- Research Site
Birmingham, Alabama, United States
- Research Site
Goodyear, Arizona, United States
- Research Site
Fort Myers, Florida, United States
- Research Site
St. Petersburg, Florida, United States
- Research Site
Tampa, Florida, United States
- Research Site
Louisville, Kentucky, United States
- Research Site
New Hyde Park, New York, United States
- Research Site
New York, New York, United States
- Research Site
The Bronx, New York, United States
- Research Site
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Mar 2018
- Primary completion
- 15 Oct 2020
- Completion
- 31 Dec 2026
- Last update posted
- 11 May 2026
- Registered enrollment
- 154
- Registry id
- NCT03459846
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.